Introduction
The mRNA cap is a critical structure in gene expression and in innate immunity. It protects pre-mRNA from exonucleases during transcription, recruits factors involved in RNA processing, nuclear export and translation, and identifies transcripts as "self" to protect against the innate immune response. Formation of the mRNA cap initiates as nascent premRNA emerges from the RNA pol II complex. The rate and extent of mRNA cap formation is regulated by cellular signalling pathways resulting in changes in cell physiology and fate.
mRNA cap formation
The mRNA cap structure was first characterized in the 1970s as a 5' blocked, methylated structure in viral mRNAs and was recognised shortly after to be a feature of eukaryotic mRNA 1, 2 . Nascent pre-mRNA is transcribed with a terminal triphosphate (ppp (5' )N, N is the first transcribed nucleotide). The terminal phosphate is removed and GMP (guanosine monophosphate) is added to create the guanosine cap intermediate (G(5')ppp(5')N). This structure has a 5' to 5' triphosphate linkage thought to be unique to RNA pol II transcripts.
Subsequently the guanosine cap is methylated on the 7'-N position and the first and second transcribed nucleotides can be methylated on the ribose 2'-O positions. More rare modifications are found in the cap structure including 6'-N methylation if the first transcribed nucleotide is adenosine 3,4 . 6'-N methylation of the 1 st nucleotide adenosine is reversible and increases transcript stability by conferring resistance to decapping enzymes. Furthermore, any other RNA modification, including 1'-N adenosine methylation, may be found on the first transcribed nucleotides, thus becoming part of a cap structure 5 . Recently novel nicotinamide adenine dinucleotide (NAD + ) caps have also been isolated on mRNA, which target the transcripts for degradation 6 .
The first step in mRNA cap formation is addition of the guanosine cap intermediate,
. This is catalysed by the sequential actions of a triphosphatase and a guanylyltransferase. The catalytic cores of the different capping enzymes are largely conserved in eukaryotes whereas the holo-enzymes have different configurations. In this review, we focus discussion on the mammalian capping enzymes. In mammals, a single enzyme, RNGTT (RNA guanylyltransferase and 5' triphosphatase) possess both triphosphatase and guanylyltransferase activities 7, 8 . Guanosine cap 7'-N methylation, creating m7G(5')ppp(5')N, is catalysed by RNMT (RNA guanine-7 methyltransferase), which is found in a complex with its activating subunit RAM (RNMT-activating miniprotein) [9] [10] [11] .
Methylation of the first and second transcribed nucleotides at the ribose 2'-O position is catalysed by CMTR1 and CMTR2, respectively 12, 13 . Whilst analyses are in agreement that m7G(5')ppp(5')Nm is the most abundant mRNA cap structure, the relative proportion of the 4 different cap methyl groups is an area of active research 6, 14, 15 . Previously, mass spectrometric analyses of cap structures were restricted to cell lines and large organs. With recent improvements in chromatography and mass spectrometry, analysis of mRNA caps in an increasing array of primary tissues and cells will be possible 16 .
mRNA cap function
Following its discovery, the mRNA cap was found to protect mRNA from exonucleases, and to recruit protein complexes involved in RNA processing, nuclear export and translation and initiation 17, 18 . In the nucleus, the binding of CBC (Cap Binding Complex) to the mRNA cap promotes pre-mRNA splicing, nuclear export and influences pre-mRNA 3' end processing and nonsense mediated decay 19 . eIF4E and the eIF4F complex also bind to the cap and promote nuclear export and translation initiation 20 . Over the last decade, formation of the mRNA cap has been recognised to be regulated in a gene-specific manner by the influence of transcription factors, signalling pathways and developmental pathways [21] [22] [23] [24] . Regulation of mRNA cap formation results in alterations in gene expression and subsequent changes in cell function and fate. Recently CMTR1 has been recognised to be regulated in the innate immune response, and to have a critical role in the recognition of self-RNA 25 . This has reinvigorated interest in 2'-O methylation of the first nucleotide ribose.
First transcribed nucleotide 2'-O methylation in gene expression

First nucleotide 2'-O methylation and splicing
The 7-methylguanosine cap binds to CBC which interacts with splicing factors and thus promotes splicing 26 . Whether 2'-O methylation of the first transcribed nucleotide of mRNA has a role in splicing remains to be seen. However, 2'-O methylation is present on the first nucleotide of U1, U2, U4 and U5 snRNAs and is important for their function in the mechanism of splicing 27 . snRNAs are RNA pol II transcripts and therefore receive a 7-methylguanosine cap. Following export into the cytoplasm, further methylation yields a (2,2,7) trimethylguanosine cap and the snRNA-protein complex (snRNP) is re-imported into the nucleus to function in splicing. In the nucleus, the snRNAs are further modified with pseudouridination, and first and internal nucleotide ribose 2'-O methylation. In vitrotranscribed U2 snRNA cannot reconstitute splicing in U2-depleted Xenopus oocytes or HeLa nuclear extract indicating that modifications of U2 snRNA are important for snRNP biogenesis and/or pre-mRNA splicing 28, 29 . Only when both the (2,2,7) trimethylguanosine cap and internal modifications are acquired does synthetic U2 snRNA become fully functional 30 . Moreover, 2′-O-methyl groups at positions 1, 2, 12, and 19, but not at position 11, are individually required for the function of U2 snRNA. The function of the 2'-O methylation is not clear, but is required for the E complex formation 31 . Interestingly, snRNPs 5 first and second nucleotide 2'-O methylation only occurs in higher eukaryotes, indicating that CMTR1 and CMTR2 are potentially involved in these methylations 32 .
First nucleotide 2'-O-methylation in mRNA translation
The 7-methyl guanosine cap is critical for eIF4E binding and translation initiation 33 . eIF4E
binds to the scaffold protein eIF4G and helicase eIF4A forming the eIF4F complex, which recruits the 40S ribosomal subunit to mRNA. First nucleotide 2'-O methylation was recognised to have a role in translation shortly after its discovery; it was demonstrated to enhance ribosome binding and translation 34, 35 . 36 . Of note, c-mos mRNA translation and resultant oocyte maturation was found to be dependent upon first nucleotide O-2 methylation 36 .
CMTR1: first nucleotide 2'-O-methyltransferase
First nucleotide 2'-O methyltransferase activity was initially characterised in vaccinia virus and HeLa cells 37, 38 . However, the methyltransferase responsible for first nucleotide Extracts of HeLa cells depleted of CMTR1 are defective for first nucleotide 2'-O methylation, indicating that there is not a completely redundant methyltransferase present in these cells 40 .
Belanger et al also reported that knock-down of CMTR1 does not impact on global translation as measured by 35 S methionine incorporation, although it is a possibility that the remaining CMTR1 may be sufficient to maintain translation. As discussed above, first nucleotide 2'-O methylation has been linked to mRNA translation in several eukaryotic systems and deletion of the 1 st and 2 nd transcribed nucleotide 2'-O-methyltransferase in
Trypanosomes results in a significant reduction in global translation 41 .
CMTR1 had previously been identified as KIA0082/ISG95, a protein implicated in the response to interferon treatment and viral infection [42] [43] [44] [45] . Following these studies CMTR1 was characterised as a multi-domain protein with a nuclear localization signal, G-patch domain, a RrmJ/FtsJ methyltransferase domain, a non-functional cap guanylyltransferase-like domain 6 and a WW domain 46 . Deletion of the domains C-terminal to the methyltransferase (guanylyltransferase-like and WW domains) reduces the activity of CMTR1 in vitro and therefore these domains are likely to contribute to substrate recruitment and/or structural configuration 39 . The CMTR1 WW domain interacts with the C-terminal domain (CTD) of the largest subunit of RNA polymerase II (RNA Pol II) 46 . Whether CMTR1 has enhanced affinity for a particular CTD phosphorylation state, remains to be determined. Since first nucleotide 2'-O-methylation does not inhibit or enhance 7'-N methylation of the cap guanosine it is not clear whether RNMT or CMTR1 methylates the cap first, or indeed whether they have an order of action.
Structural analysis of the CMTR1 catalytic domain resolved a Rossman-like fold methyltransferase domain and determined the mechanism of guanosine cap recognition 39 . In the CMTR1 active site, the methylated guanosine (m7G) is accommodated in a deep pocket and the transcribed nucleic acids adopt an L shape with nucleotide 1 located at the bend.
Analysis of the positioning of the RNA in the exit of the active site suggests that substrate binding and methylation are sequence-independent. However, whether the domains N-and Cterminal to the methyltransferase domain interact with RNA and/or other proteins, potentially providing substrate specificity, will require further exploration. As discussed above, CMTR1
has other domains (G-patch, WW and guanylyl-transferase-like) which have been demonstrated to influence activity 39 . The N-and C-terminal domains of CMTR1 are intrinsically unstructured, which to date has impaired structural characterisation of the fulllength enzyme.
CMTR1 and 2'-O-methylation in "self"-RNA distinction
In recent years, the cap1 structure (m7GpppNm) has emerged as a key factor in "self-RNA" identification during the innate immune response 47 
Regulation of CMTR1
Since CMTR1 has important roles in translation and innate immunity, its regulation is of interest. Analysis of mouse tissues revealed differences in the extent of 1 st nucleotide 2'-O methylation suggesting tissue specific regulation of CMTR1 expression or activity 15 .
CMTR1 has several domains through which subcellular localisation, activity or expression may be regulated, potentially by protein:protein interactions or by post-translational modifications. The 7'-N cap methyltransferase, RNMT-RAM, has been demonstrated to be regulated at the level of expression, recruitment to chromatin and activity 21, 23, 24, 55 .
CMTR1 expression has been observed to be upregulated during the innate immune response.
In four independent studies where an interferon response was elicited, the expression of CMTR1 was upregulated ~3-fold [42] [43] [44] [45] . Despite differences in model cell lines or organisms, upregulation of CMTR1 expression is transient and efficiently cleared after the initial antiviral response. In human fibroblasts, CMTR1 knockdown was sufficient to elicit an interferon-like innate immune response 25 .
Future perspectives : ribose O-2 methylation and disease
A causative effect for CMTR1 in human diseases has yet to be elucidated. However, significant changes in CMTR1 mRNA levels in patients experiencing asthma exacerbations have been observed, suggesting a role for CMTR1 in the pathogenesis of asthma exacerbations 56 . Highly pathogenic viruses include RNA genome-based viruses which give rise to zoonotic and epidemic diseases 57 . Inactivation of flavivirus, coronavirus and poxvirus families 2'-O MTases increased sensitivity to antiviral actions of type I IFN 58 .
Therapeutic targeting of 2'-O MTases may offer a new avenue to treat some of these viral infections.
